Patents by Inventor Francesco Berlanda Scorza
Francesco Berlanda Scorza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11339367Abstract: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.Type: GrantFiled: April 8, 2016Date of Patent: May 24, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Christiane Gerke, Francesco Berlanda Scorza, Allan Saul, Luana Maggiore
-
Patent number: 11155572Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.Type: GrantFiled: March 13, 2014Date of Patent: October 26, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berlanda Scorza, Yingxia Wen, Andrew Geall, Frederick Porter
-
Publication number: 20210214388Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.Type: ApplicationFiled: January 25, 2021Publication date: July 15, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
-
Publication number: 20180298064Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: June 26, 2018Publication date: October 18, 2018Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Hervé TETTELIN
-
Patent number: 10035826Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.Type: GrantFiled: May 9, 2016Date of Patent: July 31, 2018Assignees: GlaxoSmithKline Biologicals SA, J. Craig Venture Institute, Inc.Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20160289632Abstract: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.Type: ApplicationFiled: April 8, 2016Publication date: October 6, 2016Inventors: Christiane Gerke, Francesco Berlanda Scorza, Allan Saul, Luana Maggiore
-
Publication number: 20160244489Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: May 9, 2016Publication date: August 25, 2016Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
-
Patent number: 9334313Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.Type: GrantFiled: June 2, 2014Date of Patent: May 10, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20160024139Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.Type: ApplicationFiled: March 13, 2014Publication date: January 28, 2016Inventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
-
Publication number: 20140356389Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
-
Patent number: 8758764Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: GrantFiled: February 17, 2006Date of Patent: June 24, 2014Assignees: Novartis Vaccines and Diagnostics Srl, J. Craig Venter InstituteInventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20130052227Abstract: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.Type: ApplicationFiled: September 28, 2010Publication date: February 28, 2013Applicant: Novartis Vaccines Institute For Global Health S.R.L.Inventors: Christiane Gerke, Francesco Berlanda Scorza, Allan Saul, Luana Maggiore
-
Publication number: 20130004531Abstract: Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.Type: ApplicationFiled: September 4, 2012Publication date: January 3, 2013Applicants: Robert Koch Institute, Novartis Vaccines and Diagnostics SRLInventors: Francesco BERLANDA SCORZA, Maria Rita Fontana, Danilo Gomes Moriel, Mariagrazia Pizza, Laura Serino, Jörg Hacker
-
Publication number: 20120058146Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.Type: ApplicationFiled: November 9, 2011Publication date: March 8, 2012Applicant: Novartis Vaccines and Diagnostics SRLInventors: Danilo Gomes Moriel, Francesco Berlanda Scorza, Mariagrazia PIZZA, Laura Serino, Maria Rita Fontana
-
Patent number: 8062644Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.Type: GrantFiled: February 17, 2006Date of Patent: November 22, 2011Assignee: Novartis Vaccines & Diagnostics SRL.Inventors: Mariagrazia Pizza, Laura Serino, Francesco Berlanda Scorza, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20100166788Abstract: Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.Type: ApplicationFiled: August 15, 2007Publication date: July 1, 2010Applicant: NOVARTIS VACCINES AND DIAGNOSTICSInventors: Francesco Berlanda Scorza, Danilo Gomes Moriel, Jörg Hacker, Mariagrazia Pizza, Laura Serino, Maria Rita Fontana
-
Publication number: 20090324633Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.Type: ApplicationFiled: February 17, 2006Publication date: December 31, 2009Applicant: Novartis Vaccines and Diagnostics, S.R.L.Inventors: Maria-grazia Pizza, Laura Serino, Francesco Berlanda Scorza, Danilo Gomes Moriel, Maria Rita Fontana